Antithrombins

Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.

Also Known As:

Networked: 290 relevant articles (21 outcomes, 37 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lip, Gregory Y H: 4 articles (03/2015 - 10/2011)
2.	Steffel, Jan: 3 articles (03/2015 - 08/2009)
3.	Eikelboom, John W: 3 articles (07/2012 - 01/2002)
4.	Moliterno, David J: 3 articles (02/2012 - 02/2002)
5.	Dager, William E: 3 articles (09/2010 - 09/2003)
6.	Bauer, Kenneth A: 3 articles (09/2008 - 01/2006)
7.	Weitz, Jeffrey I: 3 articles (01/2003 - 02/2002)
8.	Haas, Sylvia: 2 articles (03/2015 - 01/2004)
9.	Robertson, Lindsay: 2 articles (01/2015 - 01/2013)
10.	Grove, Erik Lerkevang: 2 articles (12/2014 - 02/2012)

Related Diseases

1.	Hemorrhage 11/01/2011 - "Studies of direct thrombin inhibitors have hitherto concentrated on major bleeding. " 06/01/1998 - "Recent clinical trials revealed the effectiveness of direct thrombin inhibitors in various thrombotic and cardiovascular indications, but also a tendency to an increased risk of bleeding complications. " 11/01/2013 - "Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients." 11/12/2012 - "The use of anti-Xa or direct thrombin inhibitors is associated with a dramatic increase in major bleeding events, which might offset all ischemic benefits in patients receiving antiplatelet therapy after an ACS." 07/01/2012 - "We evaluated trends in use of BAS (direct thrombin inhibitors, vascular closure devices, and radial access) and risk-adjusted bleeding over time. "
2.	Thrombosis (Thrombus) 03/01/2006 - "Although direct thrombin inhibitors have been proven to be effective for the treatment of HIT thrombosis, they do not completely eliminate the morbidity and mortality of this disorder. " 05/01/2014 - "Device thrombosis remains a therapeutic dilemma, and limited data are available for the use of direct thrombin inhibitors as a treatment option. " 02/01/2005 - "Each of these variant antithrombins is associated with an increased risk of thrombosis that typically occurs in an unexpectedly severe and sudden form. " 01/01/2005 - "Direct thrombin inhibitors do not equally prevent arterial thrombosis. " 08/01/2002 - "Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model."
3.	Atrial Fibrillation 05/01/2004 - "Oral direct thrombin inhibitors are safe and effective in patients with atrial fibrillation, but this is not proven in those with prosthetic heart valves. " 03/01/2013 - "Oral direct thrombin inhibitors have improved treatment of non-valvular atrial fibrillation. " 08/01/2014 - "[Non-valvular atrial fibrillation: direct thrombin inhibitors versus VKA]." 01/01/2014 - "Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation. " 12/01/2009 - "Direct thrombin inhibitors in atrial fibrillation reloaded."
4.	Myocardial Infarction 02/15/2014 - "Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets." 12/15/2013 - "Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors." 12/01/1999 - "Recent trials demonstrate that direct antithrombins reduce rates of death and myocardial infarction early in patients without ST elevation, but the treatment effect diminishes over time. " 08/01/1995 - "Thus, it is hoped that these favorable initial results can be confirmed in the larger phase III trials and that the direct thrombin inhibitors will further improve the outcome of patients with acute myocardial infarction." 01/01/2004 - "Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction."
5.	Stroke (Strokes) 01/01/2005 - "Direct thrombin inhibitors are likely to add a user-friendly option to the current standard therapy for stroke prevention." 03/01/2012 - "Direct thrombin inhibitors have been demonstrated to be safe and effective in preventing stroke in patients with atrial fibrillation (AF) eligible for inclusion in the RE-LY trial. " 01/01/2005 - "Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties." 02/01/2013 - "Oral direct thrombin inhibitors were associated with an improved major and CRNM bleeding profile (both comparisons: RR 0.88, 95 % CI 0.78-0.98, P = 0.02) and a significant reduction in stroke and systemic embolism (against controls: RR 0.79, 95 % CI 0.66-0.93, P = 0.006; against VKAs: RR 0.78, 95 % CI 0.66-0.93, P = 0.006). " 01/01/2004 - "A number of clinical studies have investigated antithrombins for prophylaxis prior to orthopedic surgery, in the prevention of cerebrovascular accidents associated with atrial fibrillation, and in the control of coronary artery disease. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Factor Xa (Coagulation Factor Xa)
3.	argatroban (MPQA)
4.	Anticoagulants
5.	bivalirudin (Angiomax)
6.	Hirudins
7.	Warfarin (Coumadin)
8.	Vitamin K
9.	inogatran
10.	Thrombin

Related Therapies and Procedures

1.	Angioplasty (Angioplasty, Transluminal)
2.	Perioperative Period
3.	Aftercare (After-Treatment)
4.	Thrombolytic Therapy
5.	Cardiopulmonary Bypass (Heart-Lung Bypass)